Article thumbnail

Mesenchymal Stem Cells and Inflammatory Cardiomyopathy: Cardiac Homing and Beyond

By S. Van Linthout, Ch. Stamm, H.-P. Schultheiss and C. Tschöpe

Abstract

Under conventional heart failure therapy, inflammatory cardiomyopathy usually has a progressive course, merging for alternative interventional strategies. There is accumulating support for the application of cellular transplantation as a strategy to improve myocardial function. Mesenchymal stem cells (MSCs) have the advantage over other stem cells that they possess immunomodulatory features, making them attractive candidates for the treatment of inflammatory cardiomyopathy. Studies in experimental models of inflammatory cardiomyopathy have consistently demonstrated the potential of MSCs to reduce cardiac injury and to improve cardiac function. This paper gives an overview about how inflammation triggers the functionality of MSCs and how it induces cardiac homing. Finally, the potential of intravenous application of MSCs by inflammatory cardiomyopathy is discussed

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier: oai:pubmedcentral.nih.gov:3051267
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1,”
  2. (1987). A histopathologic definition and classification,”
  3. (2006). A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction,”
  4. (2004). A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow,”
  5. (2007). Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis,”
  6. (2004). Beeres et al., “Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial,”
  7. (2008). Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells,”
  8. (2010). Chico-Calero et al., “Angiotensinconverting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction,”
  9. (2001). Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1): SDF1 α mRNA is selectively induced in rat model of myocardial infarction,”
  10. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing,”
  11. (2003). Effect of stromalcell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy,”
  12. (2008). Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2,”
  13. (2009). Etzrodt et al., “Identification of splenic reservoir monocytes and their deployment to inflammatory sites,”
  14. (2004). G¨ o b e l
  15. (2010). Genetic modification of mesenchymal stem cells overexpressing ccr1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium,”
  16. (2009). H a r e ,J .H .T r a v e r s e ,T .D .H e n r ye ta l . ,“ Ar a n -domized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” J o u r n a lo ft h e
  17. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocytederived dendritic cells,”
  18. (2007). i e s ,V .E g e a ,M .K a r o w ,H .K o l b ,M .J o c h u m ,a n dP . Neth, “MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines,”
  19. (2008). Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy,”
  20. (2010). Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells,” Stem Cell Reviews and Reports,
  21. (2010). Inflammatory cytokineinduced intercellular adhesion molecule-1 and vascular cell adhesionmolecule-1inmesenchymalstemcellsarecriticalfor immunosuppression,”
  22. (2009). Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium,”
  23. (2003). Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction,”
  24. (2007). Interferon-γ and NF-κB mediate nitric oxide production by mesenchymal stromal cells,”
  25. (2004). Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms,”
  26. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues,”
  27. (2006). Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms,”
  28. (2008). Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure,”
  29. (2008). Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide,”
  30. (2007). Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions,”
  31. (2004). Mesenchymal stem cells can be differentiated into endothelial cells in vitro,”
  32. (2006). Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells,”
  33. (2006). Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair,”
  34. (2010). Mesenchymal stem cells improve murine acute Coxsackievurs B3-induced myocarditis,” European Heart Journal,
  35. (2005). Mesenchymal stem cells induce apoptosis of activated
  36. (2006). Mesenchymal stem cells transmigrate over the endothelial barrier,”
  37. (2005). Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure,”
  38. (2007). Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor,”
  39. (1999). Multilineage potential of adult human mesenchymal stem cells,”
  40. (2004). N.Nagaya,T.Fujii,T.Iwaseetal.,“Intravenousadministration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis,”
  41. (2004). Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virusinfected mice,”
  42. (2006). o n c z a r e n k o
  43. (2008). Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium,”
  44. (1996). Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets,”
  45. Peritransplant ischemic injury is associated with up-regulation of stromal cell-derived factor-1,”
  46. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1inductionofSDF-1,”Nature Medicine,vol.10,no.8,pp.
  47. (2009). Q u e v e d o ,K .E .H a t z i s t e r g o s ,B .N .O s k o u e ie ta l . , “Allogeneicmesenchymalstemcellsrestorecardiacfunctionin chronic ischemic cardiomyopathy via trilineage differentiating capacity,”
  48. (2006). r a m p e r a ,L .C o s m i ,R .A n g e l ie ta l . ,“ R o l ef o ri n t e r f e r o n -γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells,”
  49. (2007). r o i t o r u - L a m o u r y ,F .M .J .L a m o u r y ,J .J .Z a u n d e r s
  50. (2009). Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study,”
  51. (2004). Reca et al., “CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion,”
  52. (2007). Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homingefficiency
  53. (2008). S c h u l e r i ,L .C .A m a d o ,A .J .B o y l ee ta l . ,“ E a r l y improvement in cardiac tissue perfusion due to mesenchymal stem cells,”
  54. (2006). S o t i r o p o u l o u ,S .A .P e r e z ,A .D .G r i t z a p i s
  55. S.E.Haynesworth,M.A.Baber,andA.I.Caplan,“Cellsurface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies,”
  56. (2007). Safety of intramyocardial stem cell therapy for the ischemic myocardium: results of the Rostock trial after 5-year followup,”
  57. (2005). Selective down-regulation of extracellular matrix gene expression by bone marrow derived stem cell transplantation into infarcted myocardium,”
  58. (2004). Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarctionbutisnotsufficienttoinducehomingintheabsence of injury,”
  59. (1985). Systemic lymphoid atrophy in coxsackievirus B3-infected mice: effects of virus and immunopotentiating agents,”
  60. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities,”
  61. (2002). The inflammatory response in myocardial infarction,”
  62. (2007). The role of IL6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells,”
  63. (2009). The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemi,”
  64. (2007). Tissue transglutaminase is essential for integrin-mediated survival of bone marrowderived mesenchymal stem cells,”
  65. (2007). Towards in situtissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2,”
  66. (2007). Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis,”
  67. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy,”
  68. (2009). Trouche et al., “Mesenchymal stem cells promotematrixmetalloproteinasesecretionbycardiacfibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction,”